Seattle, June 22, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global influenza vaccines market is estimated to be valued at US$ 5,965.9 million in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Influenza Vaccines Market:
The increasing research and development for product and clinical trials for improvement of drug candidate expected to drive the global influenza vaccines market over the forecast period. For instance, on June 1, 2021, The National Institutes of Health (NIH) has begun a clinical trial of FluMos-v1, a universal influenza vaccine candidate that uses self-assembling nanoparticle scaffolds to display a part of the influenza virus hemagglutinin (HA) protein to stimulate antibodies against multiple influenza virus strains. At the National Institutes of Health Clinical Center in Bethesda, Maryland, a Phase 1 trial started to examine the safety and immunogenicity of an experimental nanoparticle influenza vaccine designed to give long-term protection against several flu virus strains that has commenced.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1705
Key Market Takeaways:
Increasing investment by government authorities to provide influenza vaccine is expected to drive the global influenza vaccines market over the forecast period. For instance, on March 25, 2022, the Australian government announced investment of US$ 100 million for seasonal influenza vaccines. The aim behind this investment is to protect the population from influenza and COVID-19 to minimize its impact on the healthcare in Australia.
Competitive Landscape:
Key players operating in the global influenza vaccines market include Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen, Inc., Moderna, Inc., Biocryst Pharmaceuticals, Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, and Solaris Vaccines
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1705
Market Segmentation:
- Global Influenza Vaccines Market, by Vaccine Type:
- Trivalent Vaccines
- Quadrivalent Vaccines
- Global Influenza Vaccines Market, by Virus Type:
- Influenza Virus A
- Influenza Virus B
- Global Influenza Vaccines Market, by Age Group:
- Pediatrics
- Adults
- Global Influenza Vaccines Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028
Recombinant Vaccines Market, by Product Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), by Disease Type (Infectious Disease, Cancer, Allergy, and others), by End User (Recombinant Human Vaccines and Animal Recombinant Vaccines (Poultry, Companion Animal Vaccines, Livestock, Porcine, and Aquaculture Vaccines)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030
Vaccines Market, by Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Therapy, and Recombinant Therapy), by Type (Monovalent Vaccines and Multivalent Vaccines), by Indication (Typhoid, Hepatitis, Pneumococcal, DTP, Malaria, Influenza, Human Papilloma Virus, Meningococcal, Polio, Rotavirus, MMR, Varicella, Herpes Zoster, and Others), by Route of Administration (Parenteral Administration and Oral Administration), by Age Group (Pediatric and Adult), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
